255 related articles for article (PubMed ID: 12235206)
1. Lymphangiogenic gene therapy with minimal blood vascular side effects.
Saaristo A; Veikkola T; Tammela T; Enholm B; Karkkainen MJ; Pajusola K; Bueler H; Ylä-Herttuala S; Alitalo K
J Exp Med; 2002 Sep; 196(6):719-30. PubMed ID: 12235206
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.
Saaristo A; Veikkola T; Enholm B; Hytönen M; Arola J; Pajusola K; Turunen P; Jeltsch M; Karkkainen MJ; Kerjaschki D; Bueler H; Ylä-Herttuala S; Alitalo K
FASEB J; 2002 Jul; 16(9):1041-9. PubMed ID: 12087065
[TBL] [Abstract][Full Text] [Related]
3. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
[TBL] [Abstract][Full Text] [Related]
4. Insights into the molecular pathogenesis and targeted treatment of lymphedema.
Saaristo A; Karkkainen MJ; Alitalo K
Ann N Y Acad Sci; 2002 Dec; 979():94-110. PubMed ID: 12543720
[TBL] [Abstract][Full Text] [Related]
5. A model for gene therapy of human hereditary lymphedema.
Karkkainen MJ; Saaristo A; Jussila L; Karila KA; Lawrence EC; Pajusola K; Bueler H; Eichmann A; Kauppinen R; Kettunen MI; Yla-Herttuala S; Finegold DN; Ferrell RE; Alitalo K
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12677-82. PubMed ID: 11592985
[TBL] [Abstract][Full Text] [Related]
6. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
[TBL] [Abstract][Full Text] [Related]
7. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.
Yoon YS; Murayama T; Gravereaux E; Tkebuchava T; Silver M; Curry C; Wecker A; Kirchmair R; Hu CS; Kearney M; Ashare A; Jackson DG; Kubo H; Isner JM; Losordo DW
J Clin Invest; 2003 Mar; 111(5):717-25. PubMed ID: 12618526
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin.
Enholm B; Karpanen T; Jeltsch M; Kubo H; Stenback F; Prevo R; Jackson DG; Yla-Herttuala S; Alitalo K
Circ Res; 2001 Mar; 88(6):623-9. PubMed ID: 11282897
[TBL] [Abstract][Full Text] [Related]
9. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
Veikkola T; Jussila L; Makinen T; Karpanen T; Jeltsch M; Petrova TV; Kubo H; Thurston G; McDonald DM; Achen MG; Stacker SA; Alitalo K
EMBO J; 2001 Mar; 20(6):1223-31. PubMed ID: 11250889
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.
Mäkinen T; Jussila L; Veikkola T; Karpanen T; Kettunen MI; Pulkkanen KJ; Kauppinen R; Jackson DG; Kubo H; Nishikawa S; Ylä-Herttuala S; Alitalo K
Nat Med; 2001 Feb; 7(2):199-205. PubMed ID: 11175851
[TBL] [Abstract][Full Text] [Related]
11. Lymphangiogenic growth factors, receptors and therapies.
Lohela M; Saaristo A; Veikkola T; Alitalo K
Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
[TBL] [Abstract][Full Text] [Related]
12. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane.
Oh SJ; Jeltsch MM; Birkenhäger R; McCarthy JE; Weich HA; Christ B; Alitalo K; Wilting J
Dev Biol; 1997 Aug; 188(1):96-109. PubMed ID: 9245515
[TBL] [Abstract][Full Text] [Related]
13. Growth factor therapy and lymph node graft for lymphedema.
Tervala TV; Hartiala P; Tammela T; Visuri MT; Ylä-Herttuala S; Alitalo K; Saarikko AM
J Surg Res; 2015 Jun; 196(1):200-7. PubMed ID: 25777822
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis.
Karkkainen MJ; Petrova TV
Oncogene; 2000 Nov; 19(49):5598-605. PubMed ID: 11114740
[TBL] [Abstract][Full Text] [Related]
15. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.
Mäkinen T; Veikkola T; Mustjoki S; Karpanen T; Catimel B; Nice EC; Wise L; Mercer A; Kowalski H; Kerjaschki D; Stacker SA; Achen MG; Alitalo K
EMBO J; 2001 Sep; 20(17):4762-73. PubMed ID: 11532940
[TBL] [Abstract][Full Text] [Related]
16. Utilization of Vascular Endothelial Growth Factor-C156S in Therapeutic Lymphangiogenesis: A Systematic Review.
Forte AJ; Boczar D; Huayllani MT; Anastasiadis PZ; McLaughlin S
Lymphat Res Biol; 2022 Dec; 20(6):580-584. PubMed ID: 35501971
[No Abstract] [Full Text] [Related]
17. Molecular regulation of lymphangiogenesis and targets for tissue oedema.
Karkkainen MJ; Jussila L; Ferrell RE; Finegold DN; Alitalo K
Trends Mol Med; 2001 Jan; 7(1):18-22. PubMed ID: 11427983
[TBL] [Abstract][Full Text] [Related]
18. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.
Paavonen K; Mandelin J; Partanen T; Jussila L; Li TF; Ristimaki A; Alitalo K; Konttinen YT
J Rheumatol; 2002 Jan; 29(1):39-45. PubMed ID: 11824969
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
